Janus Henderson Group PLC Buys New Shares in Maplight Therapeutics, Inc. $MPLT

Janus Henderson Group PLC purchased a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 54,752 shares of the company’s stock, valued at approximately $1,113,000. Janus Henderson Group PLC owned about 0.13% of Maplight Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Strs Ohio purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the 4th quarter worth approximately $70,000. New York State Common Retirement Fund bought a new position in Maplight Therapeutics during the 4th quarter worth approximately $93,000. MetLife Investment Management LLC purchased a new position in Maplight Therapeutics in the 4th quarter worth approximately $172,000. Finally, Walleye Capital LLC bought a new stake in Maplight Therapeutics in the fourth quarter valued at approximately $205,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MPLT shares. Wall Street Zen lowered Maplight Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Stifel Nicolaus increased their price target on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Needham & Company LLC raised their price target on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, July 10th. BMO Capital Markets assumed coverage on shares of Maplight Therapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maplight Therapeutics in a report on Monday, July 13th. Four investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.17.

Insider Activity at Maplight Therapeutics

In other news, Director Troy Cox purchased 15,620 shares of Maplight Therapeutics stock in a transaction that occurred on Tuesday, July 28th. The shares were bought at an average cost of $9.52 per share, with a total value of $148,702.40. Following the completion of the purchase, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James Woodruff Lillie sold 22,082 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $12.54, for a total value of $276,908.28. Following the completion of the sale, the insider directly owned 202,380 shares in the company, valued at $2,537,845.20. This trade represents a 9.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by corporate insiders.

Maplight Therapeutics Trading Up 0.1%

Shares of MPLT opened at $12.18 on Tuesday. Maplight Therapeutics, Inc. has a 1-year low of $9.10 and a 1-year high of $40.43. The firm’s 50-day moving average price is $28.65 and its 200-day moving average price is $24.71. The firm has a market capitalization of $519.09 million and a price-to-earnings ratio of -0.30.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, research analysts forecast that Maplight Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.